Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC 23: The STOPDAPT-3 Study
Author(s): Masahiro Natsuaki Added: 7 months ago
ESC 23 — Dr Masahiro Natsuaki (Saga University, JP) discusses the short and optimal duration of dual antiplatelet therapy-3 Study (STOPDAPT-3) (NCT04609111). In the STOPDAPT-2 study, 1-month dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy was shown to provide benefits in bleeding reduction over a 12-month period, however, other trials have shown high rates of bleeding at… View more

MI/ACS

Intervention
Author(s): Suzanne J Baron , Robert P Giugliano Added: 3 years ago
Coronary artery disease remains the leading cause of death in the US and worldwide. Although the incidence of death due to coronary artery disease has declined over the last several years, the prevalence of coronary artery disease remains high, with the American Heart Association (AHA) estimating that over 81 million Americans suffer from cardiovascular disease and 2,200 people dying every day of… View more

Anticoagulation
2020 APSC Consensus Recommendations on P2Y12 Inhibitor Use
Author(s): Jack Wei Chieh Tan , Derek P Chew , Muhamad Ali SK Abdul Kader , et al Added: 3 years ago

Anticoagulation

Standards & Guidelines
Author(s): Patrick Wong , Umair Shafique Added: 3 years ago
Cardiovascular (CV) events are a major cause of mortality worldwide1 that are often precipitated by acute coronary syndromes (ACS). ACS result from the acute obstruction of coronary arteries and are defined as either unstable angina (UA) or myocardial infarction (MI), with or without ST-segment-elevation (STEMI and NSTEMI, respectively). Patients with moderate- to high-risk ACS are managed by an… View more

Anticoagulation

MI/ACS
Author(s): Diego Penela , Maríbel Diaz-Ricart , Magda Heras Added: 3 years ago
The usual underlying mechanism of acute coronary syndromes (ACSs) is a thrombotic event caused by the rupture or erosion of an atherosclerotic plaque. In this scenario, platelets and thrombin are key players. Thus, understanding the physiopathology of platelet activation is of paramount importance in the treatment of acute coronary ischaemia. There is ample evidence showing that adequate… View more

Anticoagulation

MI/ACS
Author(s): Sasha Koul , David Erlinge Added: 3 years ago
Acute coronary syndromes (ACS) are a major reason for death and morbidity in the industrialised world. One of the most successful treatments for ACS has been strategies to target the platelets and inhibit their function. Mechanisms of Platelet Activation Thrombus formation in the arteries is dependent on platelets and their ability to attach to the injured wall despite the rapid arterial blood… View more

Anticoagulation

MI/ACS
Author(s): Doreen Su-Yin Tan Added: 3 years ago
Ischaemic heart diseases (IHD) – mainly MI – represent a large disease burden all over the world. Almost 18 million people die each year from cardiovascular diseases, accounting for 31 % of deaths globally.1 Ticagrelor, the more potent cousin of antiplatelet therapy clopidogrel, has been shown to reduce the composite endpoint of death from vascular causes, MI or stroke by an additional 16 %… View more

Prevention & Chronic Conditions
Author(s): Laurent Bonello Added: 3 years ago
Clopidogrel is a key antiplatelet agent that inhibits the second step of platelet aggregation through blockade of the P2Y12-adenosine diphosphate (ADP) receptor.1 Its use has enabled percutaneous coronary intervention (PCI) to expand by dramatically reducing thrombotic complications in acute coronary syndromes (ACSs).2,3 Since the first report by Jaremo et al. of a large inter-individual… View more

Anticoagulation

MI/ACS
Author(s): Franz-Josef Neumann Added: 3 years ago
Acute coronary syndromes (ACS) have been associated with the occurrence of cardiovascular (CV) events. Moderate- to high-risk ACS are generally managed by an early invasive approach, where coronary angiography is followed by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). However, ACS and the use of PCI or CABG are associated with a high risk of thrombotic… View more

Anticoagulation

MI/ACS
Author(s): Thomas O Bergmeijer , Jochem Wouter van Werkum , Udaya S Tantry , et al Added: 3 years ago
Coronary angiography and subsequent percutaneous coronary intervention (PCI) is the appropriate treatment in many patients with moderate- and high-risk acute coronary syndromes (ACS). As ACS and complications after PCI are primarily platelet-driven, adequate antiplatelet therapy is of utmost importance in patients with ACS and after coronary stent implantation. The main antiplatelet agents… View more

Anticoagulation

Imaging & Diagnostics